| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $17.2M | +33.0% |
| SG&A Expense | $2.2M | -27.2% |
| Operating Income | -$19.4M | -21.5% |
| Net Income | -$19.4M | -22.6% |
| EPS (Basic) | -$1.43 | -18.2% |
| EPS (Diluted) | -$1.43 | -18.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $6.2M | +51.0% |
| Current Assets | $6.2M | +51.0% |
| Total Assets | $6.2M | +50.9% |
| Current Liabilities | $5.8M | +273.4% |
| Total Liabilities | $5.8M | +273.4% |
| Stockholders' Equity | $353K | -86.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$9.9M | -36.4% |
| Financing Cash Flow | $12.0M | +174.6% |